Characterization of a secretory phospholipase A2 in human bronchoalveolar lavage fluid

Experimental Lung Research

Volumn 22, Issue 3, 1996, Pages 299-315

  Samet, James M ^a   Madden, Michael C ^a,c   Fonteh, Alfred N ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

arachidonic acid; lavage; lung; phospholipase A2; platelet activating factor

Indexed keywords

PHOSPHOLIPASE A2;

ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG LAVAGE; PRIORITY JOURNAL;

EID: 0030014132     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149609031777     Document Type: Article

References (67)

1. Murphy RC, Sala A. Biochemistry of lipid mediators in the lung. In: Parent RA, ed. Comparative Biology of the Lung: Treatise on Pulmonary Toxicology, Vol. 1. Boca Raton, FL: CRC Press; 1991:427-449.
2. Voelkel NK, Stenmark KR, Wescott J, Chang SW. Lung eicosanoid metabolism. Clin Chest Med. 1989;10:95-105.
3. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis. 1987; 136:985-998.
4. Cuss F, Dison CM, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial hyperresponsiveness in man. Lancet. 1986;2:189-192.
5. Benveniste J. A role for PAF-acether (platelet activating factor) in bronchial hyperreactivity. Am Rev Respir Dis. 1987;135:52-54.
6. Braquet P, Rola-Pleszczynski M. Platelet activating factor and cellular immune responses. Immunol Today. 1987;8:345-352.
7. 2 and its regulating factors. New York: Plenum; 1990.
8. 2. Biochim Biophys Acta. 1988;959:269-279.
9. Suga K, Kawasaki T, Blan ML, Snyder F: An arachidonovl (polyenoid)-specific phospholipase A2 activity regulates the synthesis of platelet activating factor in granulocytic HL-60 cells. J Biol Chem. 1990;265:12363-12371.
10. 2. J Biol Chem. 1994;269:13057-13060.
11. 2 in cultured mast cells. J Biochem. 1992;111:175-181.
12. 2 activities in canine vascular smooth muscle. Biochim Biophys Acta. 1992;1165:167-176.
13. 2. J Biol Chem. 1989;264:5768-57775.
14. 2. J Biol Chem. 1991;266:14850-14853.
15. 2. J Biol Chem. 1990;265:10622-10630.
16. 2s containing 16 cysteines. J Biol Chem. 1994;269:23018-23024.
17. 2. J Biol Chem. 1994;269: 2365-2358.
18. 2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol. 1994;152:5348-5446.
19. 2. FEBS Lett. 1991;294: 247-251.
20. 2 in granules and secrete active enzyme in response to soluble stimuli. Biochem Biophys Res Commun. 1995;208:650-656.
21. Kramer RM, Johansen B, Hession C, Pepinsky RB. Characterization of a secretable phospholipase A2 from human platelets. In: Samuelsson B, et al. eds. Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 20. New York: Raven; 1990:79-86.
22. 2 from human synovial fluid in rheumatoid arthritis. J Biochem. 1989;105:395-399.
23. 2 in human neutrophil cytosol. Biochim Biophys Acta. 1993;1168:37-44.
24. 2+-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65: 1043-1051.
25. 2 recombinant overexpression enhances stimulated arachidonic acid release. Biochim Biophys Res Commun. 1991;178:1298-1305.
26. 2 by P388D1 cells. J Biol Chem. 268:21875-21882, 1993.
27. 2 from spleen, lung and kidney. Biochem J. 1993;294:261-270.
28. 2 mRNA in rat gastric mucosa and lung. Biochim Biophys Acta. 1989;1007:124-126.
29. 2 activity in rat lung supernatant. Biochim Biophys Acta. 1972;280:552-558.
30. Seilhamer JJ, Randall TL, Yamanaka M, Johnson LK. Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung. DNA. 1986;5: 519-527.
31. 2 during phenotypic transformation of cultured type II pneumocytes. Am J Physiol. 1994;266:C382-C390.
32. 2 by guinea pig alveolar macrophages. J Immunol. 1993;151:5613-5623.
33. 2. J Clin Invest. 1994;93:571-577.
34. 2 activities in human platelet, monocyte and neutrophil. Biochem Cell Biol. 1993;71:331-339.
35. 2 propepetide in acute lung injury. Lancet. 1994;344:1472-1473.
36. 2. J Appl Physiol. 1989;66:261-267.
37. 2 in the perfused guinea pig lung. J Appl Physiol. 1989;67:2495-2503.
38. 2. Am Rev Respir Dis. 1991;143:1102-1109.
39. 2 via its specific binding site. FEBS Lett. 1992; 303:217-220.
40. 2s on guinea pig lung pleural strips. J Pharmacol Exp Therap. 1993;266:1147-1155.
41. 2 in sheep with acute lung injury after high dose endotoxin infusion. Am Rev Respir Dis. 1993;148:878-881.
42. Rami J, Brondel L, Riviere U, Besombes JP. Effect of quinacrine on lipid content of bronchoalveolar lavage fluid in guinea pig sensitized to ovalbumin. Exp Lung Res. 1990;16:111-119.
43. 2 inhibitor decreases generation of thiobarbituric acid reactive substance during lung ischemia-reperfusion. Biochim Biophys Acta. 1993;1167:56-62.
44. 2 activity in the mouse lung. Am J Pathol. 1991;138:195-202.
45. Holm BA, Keicher L, Liu M, Sokolowski J, Enhornin G. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol. 1991;71:317-321.
46. Zhou W, McCollum MO, Levine BA, Olson MS. Role of platelet activating factor in pancreatitis-associated acute lung injury in the rat. Am J Pathol. 1992;140:971-979.
47. Shin MH, Averill FJ, Hubbard WC, et al. Nasal allergen challenge generates 1-O-hexadecyl-2-lyso-sn-glycero-3-phosphocholine. Am J Respir Crit Care Med. 1994;149:660-666.
48. 2 into nasal fluids after allergenic challenge: possible role in the regulation of platelet activating factor release. J Allergy Clin Immunol. 1994;94:109-119.
49. 2 from human nasal lavage. Am J Respir Cell Mol Biol. 1994;11:108-113.
50. 4 and interleukin-8 in human immunodeficiency virus-related pulmonary disease. Chest. 1993;104:763-769.
51. Hoffman AGD, Lawrence MG, Ognibine FP, et al. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest. 1992;102:1730-1736.
52. Offenstadt G, Pinta P, Masliah J, Alcindor LG, Hericord P, Amstutz P. Phospholipasic and prophospholipasic activities in bronchoalveolar lavage fluid in severe acute pulmonary disease with or without ARDS. Intensive Care Med. 1981;7:285-290.
53. Koren HS, Devlin RB, Graham DE, et al. Ozone-induced inflammation in the airways of human subjects. Am Rev Respir Dis. 1989;139:407-415.
54. Bligh EG, Dyer WT. A rapid method of total lipid extraction and purification. Can J Physiol. 1959;37:911-915.
55. Aveldano MI, VanRollins M, Horrocks LA. Separation and quantitation of free fatty acids and fatty acid methyl esters by reverse phase high pressure liquid chromatography. J Lipid Res. 1983;24:83-93.
56. 2 activity in the mouse lung. Exp Mol Pathol. 1988;49:141-151.
57. 2(s): comparison of arachidonoyl-selective and non-selective enzymes. FASEB J. 1993;7:339-745.
58. 2. J Biol Chem. 1988;263:5732-5737.
59. 2. Biochim Biophys Acta. 1990;1044:139-146.
60. 2 from guinea pig lung. Biochim Biophys Acta. 1990;1047:271-283.
61. 2 in the human lung. Am Rev Respir Dis. 1993;147:A664.
62. Dhanireddy R, Kikukawa F, Mukherjee AB. Detection of a rabbit uteroglobin-like protein in human neonatal tracheobronchial washings. Biochim Biophys Res Commun. 1988;152: 1447-1454.
63. Singh G, Katyal SL, Brown WE, Kennedy AL, Singh U, Wong-Chong MI. Clara cell kDa protein (CC10): comparison of structure and function to uteroglobin. Biochim Biophys Acta. 1990;1039:348-355.
64. 2-inhibitory protein. J Clin Invest. 1993;92:2099-2109.
65. 2 by lung surfactant protein. Biochim Biophys Acta. 1994;1211:256-262.
66. 2 activity in rats. J Clin Invest. 1993;92:1974-1980.
67. De Caterina R, Sicara R, Giannessi D, et al. Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids. J Appl Physiol. 1993;75:2368-2375.